Sugi Predict

Sugi Predict / Compounds / SCHEMBL6990889

SCHEMBL6990889

SCHEMBL6990889

CC(C)(Cc1ccccc1)C(NC(=O)COc1ccccc1)Nc1c(Nc2cccnc2)c(=O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 4/20 0.50
▸ GALR3 O60755 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ MAPKAPK2 P49137 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ PSMB5 P28074 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6988051 0.91 NOTUM (0.54) NOTUMGALR3RAB9ATDP1KDM4E
SCHEMBL7092751 0.87 CYP3A4 (0.43) NOTUMMAPKAPK2POLBLMNAMAPK1
SCHEMBL6987656 0.85 MAPKAPK2 (0.49) RAB9AMAPKAPK2MEN1KMT2AGAA
SCHEMBL7554249 0.84 MAPKAPK2 (0.52) RAB9AKDM4EMAPKAPK2MEN1KMT2A
SCHEMBL7166445 0.84 MAPKAPK2 (0.41) MAPKAPK2MAPK1
SCHEMBL7555228 0.84 MAPKAPK2 (0.45) RAB9AMAPKAPK2GAALMNAMAPK1
SCHEMBL6988947 0.82 PLK1 (0.44) MAPKAPK2MEN1KMT2AGAAMAPT
SCHEMBL6991614 0.81 ABCC9 (0.52) KDM4EMAPKAPK2MEN1KMT2AMAPT
SCHEMBL6989499 0.81 MAPKAPK2 (0.45) MAPKAPK2MEN1KMT2AMAPTLMNA
SCHEMBL6986346 0.81 MAPKAPK2 (0.45) MAPKAPK2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 — — EP claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 — — US claimed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 — — US claimed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 — — WO claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 — — US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 NOTUM 3318/4885GALR3 3205/4885RAB9A 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.